Cortical EEG Frequency

Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic

Cortical EEG activity can be recorded from chronically implanted rats and mice, and evaluated as a function of frequency to characterize or compare the effects of psychoactive drugs such as benzodiazepines, NMDA antagonists, etc.

EEG activity (0.03 – 100 Hz) is recorded for 24 h or more, and evaluated over discrete frequency ranges and time periods depending on the observed drug effects.

EEG activity (0.03 – 100 Hz) in diazepam and vehicle treated mice.

Raw EEG data is analyzed by Fourier analysis to derive EEG power as a function of frequency. Raw data (left) shows typical reduction in power with frequency (average over 90 min prior to dosing). Middle graph shows the same data subdivided into 7 discrete frequency ranges and normalized across animals. Right-most graph is normalized data with the vehicle group subtracted showing no pre-dosing difference between groups.

EEG power at specific time intervals following diazepam treatment in mice.

Graphs above are vehicle-subtracted curves of EEG power at the indicated times after treatment with diazepam (5mg/kg IV) in rats. Note the initial increase in low frequency power at 5 minutes, reversal at 60 minutes and reversal again at 540 minutes. Also note the general reciprocity of effects below 30 Hz (where increased power is associated with sleep or sedation) versus above 30 Hz, which is associated with wake or cognition.

This video represents a 3D view of EEG power as a function of frequency and time relative to dosing (-110 min = average over 90 min prior to dosing). Drug effects can be compared using 3-factor ANOVA

Interested in evaluating Cortical EEG Frequency in mice or rats?

If you are interested in learning more about the Cortical EEG Frequency, please contact us to start the conversation today!

Discuss your project with us

We chose Melior Discovery because they were responsive and cost effective. We are staying with them as a chosen scientific partner because of their thoughtful scientific input to experimental design and attention to detail. Their expertise and flexibility allowed us to quickly adapt the study design and evaluate additional outcome measures to pursue unexpected activity.
Sridharan Rajamani, Ph.D., Senior Research Scientist
Gilead Sciences
I have been working with Melior on a number of projects over the course of a few years now. They have been a great partner throughout this time. The scientists whom I have worked with have been great problem-solvers and were customer focused
Jay Lichter
Avalon Ventures
[We] have been impressed with [Melior’s] ability to rapidly and effectively evaluate compounds in animal models…as we strive to identify compounds to ameliorate the devastating symptoms of Rett,
Monica Coenraads, Executive Director
Rett Syndrome Research Trust
Melior is more than just a service company. Their experienced staff guided us in our drug development efforts. We consider Melior an extension of our own research team.
Josh Schultz
Carolus Therapeutics
Addex Therapeutics has been collaborating with Melior Discovery for more than a year. The studies performed at Melior are always carefully planned and skilfully executed while the progress of the project is well-tracked and communicated to the customer. On several occasions, when testing our compounds in a new in vivo assay, we relied on Melior's scientists in their guidance and advice. We have been particularly pleased with a series of experiments involving assessment of compounds' profiles in the rat sleep/wake EEG. This approach, that has a translational relevance, offered a sensitive measure of a compound's efficacy and side-effects
Mikhail Kalinichev, Ph.D., Associate Research Director
Addex Therapeutics
Having worked with Melior quite extensively over the past several years, we find the team to be highly knowledgeable, responsive and adaptable to our needs. The overall process has been highly efficient and we are impressed by the quality of their reports
Christopher Prior, Ph.D., CEO,
PhaseBio Pharmaceuticals Inc.
…to evaluate our lead compound in an EEG-based sleep wake model. Melior’s very experienced team provided valuable insights and recommendations on study design, analysis and interpretation of the data. As a virtual company, Prexa relied on Melior to become an extension of our knowledge team and they met all our expectations
Pat Baskin and Ev Graham
Prexa Pharmaceuticals
State of-the-art Preclinical Pharmacology
Melior provided State-of-the-art Preclinical Pharmacology Support for a period of nearly a year where a series of in vivo studies were completed on a weekly basis. The staff was extremely user-friendly and the operational processes were excellent. I can recommend Melior without reservation.
Richard DiMarchi, PhD
Cox Professor of Chemistry & Gil Chair in Biomolecular Sciences Indiana University, Department of Chemistry